Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CD40.HIVRI.Env (VRIPRO) in Previous HVTN 706 Participants
NCT06665646Phase 1Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2025
- Primary completion
- Nov 2027
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of CD40.HIVRI.Env in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local signs and symptoms at 14 days, Systemic reactogenicity signs and symptoms at 14 days and 8 more. Started Sep 2025; status: recruiting.
02
Drugs
CD40.HIVRI.Env
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06665646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665646.